The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)


Final results from the REPRISE I study: five-year clinical outcomes with the repositionable and fully retrievable LOTUS valve system

EuroIntervention 2018;14:e1180-e1182 published online September 2018 published online e-edition December 2018. DOI: 10.4244/EIJ-D-18-00664

1. MonashHEART, Monash Health, Monash Medical Centre & Monash University, Melbourne, Victoria, Australia; 2. GenesisCare HeartCare, Sydney, NSW, Australia; 3. St. Vincent’s Hospital (Melbourne), Fitzroy, Victoria, Australia; 4. Department of Cardiology, Royal Adelaide Hospital, Adelaide, SA, Australia; 5. Boston Scientific Corporation, Marlborough, MA, USA

Among patients with severe calcific aortic valve stenosis who are at high risk for surgical intervention, transcatheter aortic valve replacement (TAVR) is a safe and effective treatment option1,2. The REPRISE I feasibility study3 was designed to assess the acute safety and performance of TAVR with the mechanically expandable, fully repositionable and retrievable LOTUS™ valve (Boston Scientific, Marlborough, MA, USA). In addition to controlled mechanical expansion, which facilitates precise positioning, the valve has a unique adaptive seal, resulting in minimal paravalvular aortic regurgitation. This report of five-year outcomes from the REPRISE I study represents the longest-term data available to date for the LOTUS valve.

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
Impact of retrograde approach on long-term clinical outcomes of patients undergoing coronary chronic total occlusion interventions

Latest news